Ascendis Pharma's YORVIPATH receives UK MHRA approval for chronic hypoparathyroidism treatment.
Ascendis Pharma's YORVIPATH (palopegteriparatide) has received UK MHRA approval for the treatment of adults with chronic hypoparathyroidism in Great Britain. YORVIPATH, a prodrug of parathyroid hormone (PTH 1-34), is administered once daily and has also been granted orphan drug status. The MHRA's decision is based on the same dossier submitted to the European Medicines Agency, leading to EU authorization in November 2023.
April 24, 2024
4 Articles